Comparison of ISHAGE protocol CD34 cell enumeration with a lineage negative backgating technique

被引:4
作者
Pirruccello, SJ [1 ]
Page, CJ [1 ]
Bishop, MR [1 ]
Letheby, BA [1 ]
Warkentin, PI [1 ]
Jackson, JD [1 ]
Kessinger, A [1 ]
机构
[1] Univ Nebraska, Med Ctr, Nebraska Med Ctr 983135, Omaha, NE 68198 USA
关键词
CD34; ISHAGE; flow cytometry; lineage gating;
D O I
10.1080/0032472031000141263
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background CD34(+) cell enumeration in PBSC apheresis products has become the standard for assessing graft hematopoietic potential. Methods In in-house, three color; lineage negative-gating technique [University of Nebraska Medical Center (UNMC) protocol] for CD34 cell enumeration was compared with the ISHAGE protocol over 100 apheresis products. Cell doses determined by both methods were compared with each other and to colony-forming units-granulocyte/macrophage (CFU-GM) assay results. Results Overall, the assays compared well with each other for samples with CD34 cell doses >0.2 x 10(6)/kg (r values >0.8). The ISHAGE method showed a constant negative bias, with a mean of 38% in comparison to the UNMC protocol which was more linear at lower cell doses. Both assays showed similar correlation with CFU-GM doses after log conversion (UNMC, r = 0.915; ISHAGE, r = 0.917). When comparing integer values, however the ISHAGE method correlated with CFU-GM only in the high nose range (CFU-GM > 2 x 10(4)/kg), while the UNMC method correlated across the entire measured range of CFU-GM doses. Finally, an inter-technologist gating reproducibility study (n = 6) yielded a 23% coefficient of variation (CV) for the ISHAGE method and a 7% CV for the UNMC method, when the same two sets of CD34 histograms were analyzed to calculate cell dose. Discussion In this study the lineage negative protocol (UNMC) had a larger dynamic range, correlated better with CFU-GM results and showed better inter-technologist reproducibility than the ISHAGE method.
引用
收藏
页码:279 / 286
页数:8
相关论文
共 47 条
[1]   CD34 counts to predict the adequate collection of peripheral blood progenitor cells [J].
Armitage, S ;
Hargreaves, R ;
Samson, D ;
Brennan, M ;
Kanfer, E ;
Navarrete, C .
BONE MARROW TRANSPLANTATION, 1997, 20 (07) :587-591
[2]  
Barnett D, 1998, BRIT J HAEMATOL, V102, P553
[3]  
Bender J G, 1992, J Hematother, V1, P329, DOI 10.1089/scd.1.1992.1.329
[4]   Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factor [J].
Bishop, MR ;
Tarantolo, SR ;
Jackson, JD ;
Anderson, JR ;
SchmitPokorny, K ;
Zacharias, D ;
Pavletic, ZS ;
Pirruccello, SJ ;
Vose, JM ;
Bierman, PJ ;
Warkentin, PI ;
Armitage, JO ;
Kessinger, A .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) :1601-1607
[5]  
Brecher M E, 1996, J Hematother, V5, P227, DOI 10.1089/scd.1.1996.5.227
[6]  
Chang A, 1996, J Hematother, V5, P605, DOI 10.1089/scd.1.1996.5.605
[7]   Peripheral blood CD34+ cell count reliably predicts autograft yield [J].
Chapple, P ;
Prince, HM ;
Quinn, M ;
Bertoncello, I ;
Juneja, S ;
Wolf, M ;
Januszewicz, H ;
Brettell, M ;
Gardyn, J ;
Seymour, C ;
Venter, D .
BONE MARROW TRANSPLANTATION, 1998, 22 (02) :125-130
[8]  
DHondt L, 1997, CYTOKINES CELL MOL T, V3, P21
[9]   Circulating CD34(+) cell counts as predictive parameter for the efficacy of peripheral stem cell apheresis in Ewing tumor patients [J].
Engel, BC ;
Laws, HJ ;
Dirksen, U ;
Kramm, CM ;
Gobel, U ;
Burdach, SEG .
KLINISCHE PADIATRIE, 1997, 209 (04) :186-190
[10]   Quantification of CD34+ cells: comparison of methods [J].
Fritsch, G ;
Printz, D ;
Stimpfl, M ;
Dworzak, MN ;
Witt, V ;
Potschger, U ;
Buchinger, P .
TRANSFUSION, 1997, 37 (08) :775-784